← Eichor
Condition: Hemophilia A Severe Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Hemophilia A Severe

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Pr
Phase 4 · 2 location(s) · Sanofi · NCT06145373A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265)
Phase 1/Phase 2 · 44 location(s) · Regeneron Pharmaceuticals · NCT06379789Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
Phase 4 · 18 location(s) · Octapharma · NCT05935358Liver Biopsy In Haemophilia Gene Therapy
NA · 1 location(s) · University College, London · NCT04817462A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
Phase 1/Phase 2 · 2 location(s) · Hoffmann-La Roche · NCT07226206Long-term Anticoagulation in a Patient With Severe Hemophilia A
Phase N/A · 1 location(s) · University Hospital, Strasbourg, France · NCT07314983Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab
Phase N/A · 1 location(s) · Christoph Königs · NCT05802836Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.
Phase 3 · 19 location(s) · Hangzhou Gensciences Biopharmaceutical Co., Ltd. · NCT07684898Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa
Phase 3 · 21 location(s) · Swedish Orphan Biovitrum · NCT06716814Pharmacokinetic-guided Dosing of Emicizumab
Phase 4 · 8 location(s) · Kathelijn Fischer · NCT06320626Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
Phase 3 · 28 location(s) · Hangzhou Gensciences Biopharmaceutical Co., Ltd. · NCT06142552A Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A
Phase N/A · 1 location(s) · Tri-Service General Hospital (TSGH) · NCT05981274Multidimensional Assessment of Chronic Pain in Severe Haemophilia A
Phase N/A · 1 location(s) · Investigación en Hemofilia y Fisioterapia · NCT07096349Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VII
Phase N/A · 10 location(s) · Wayne State University · NCT05022459A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With
Phase 1/Phase 2 · 14 location(s) · Hoffmann-La Roche · NCT05987449Hemophilia A Research Program
Phase N/A · 1 location(s) · University of Washington · NCT07414511A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.
Phase 1 · 7 location(s) · Pfizer · NCT06703606Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.
Phase 3 · 1 location(s) · Sinocelltech Ltd. · NCT07437404Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment
Phase 3 · 24 location(s) · Hangzhou Gensciences Biopharmaceutical Co., Ltd. · NCT07663903ASC618 Gene Therapy in Hemophilia A Patients
Phase 1/Phase 2 · 1 location(s) · ASC Therapeutics · NCT04676048Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A
Phase 1 · 12 location(s) · Bleeding and Clotting Disorders Institute Peoria, Illinois · NCT05500807A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
Phase 3 · 34 location(s) · Pfizer · NCT05611801Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
Phase 3 · 75 location(s) · Pfizer · NCT05145127Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A
Phase N/A · 4 location(s) · Washington Institute for Coagulation · NCT04131036
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.